NCT06294847View on ClinicalTrials.gov

Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery

PHASE3RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 20, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

November 30, 2027

Conditions
Retinal Detachment
Interventions
DRUG

Ursolvan

single dose of Ursolvan® (10mg/kg) orally within 24 hours before the surgical intervention, followed by a daily dose of 10mg/kg in two divided doses for 30 days.

DRUG

Placebo

Patients will receive a single dose of placebo orally within 24 hours before the surgical intervention, followed by two doses per day for 30 days

Trial Locations (2)

75014

RECRUITING

Hôpital Cochin, Paris

92150

RECRUITING

Hôpital Foch, Suresnes

All Listed Sponsors
lead

Hopital Foch

OTHER